Answers are grounded in this paper and cite their sources.
In this analysis we aimed to assess disease control of moderate-to-severe atopic dermatitis (AD) in adults using the simple and pragmatic patient-reported outcome of well-controlled weeks We found that AD patients receiving dupilumab plus topical corticosteroids (TCS) reported superior disease control during a 52-week treatment period, as assessed by patient-reported wellcontrolled weeks, compared to patients receiving placebo plus TCS
No takes yet. Share an insight, caveat, or question.
Wu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: